Kar, P KArora, P NRamasastry, C VDhaka, R S1994-10-012009-05-311994-10-012009-05-311994-10-01Kar PK, Arora PN, Ramasastry CV, Dhaka RS. A clinicopathological study of multidrug therapy in borderline tuberculoid leprosy. Journal of the Indian Medical Association. 1994 Oct; 92(10): 336-7http://imsear.searo.who.int/handle/123456789/101374A study was undertaken to evaluate the efficacy of multidrug therapy as per WHO recommendation in 50 fresh cases (46 males and 4 females) suffering from borderline tuberculoid leprosy. All were given multidrug therapy consisting of rifampicin 600 mg once a month and dapsone 100 mg daily for 6 months. At the end of 6 months all were evaluated clinically and histopathological examinations of the lesions were studied. The lesions were still active in 60% of patients clinically; 32% cases receiving multidrug therapy had shown marked improvement. Histologically lymphocytic infiltration in skin still persisted in all the slides examined and nerve infiltration was still present in 68% of cases at the end of 6 months after receiving multidrug therapy. The study shows that treatment with multidrug regimen for 6 months may not be sufficient to treat borderline tuberculoid leprosy cases.engAdolescentAdultDapsone --therapeutic useDrug Therapy, CombinationFemaleHumansLeprosy, Borderline --drug therapyLeprosy, Tuberculoid --drug therapyMaleMiddle AgedProspective StudiesRifampin --therapeutic useTreatment OutcomeJournal Article